In this study, we aim to examine a panel of molecular markers including IDH1/2 mutation, 1p/19q codeletion, TERTp mutation and EGFR amplification as to their impact on the prognostic value of histological grade in a cohort of lower-grade gliomas. This evidence concerns the gene EGFR and central nervous system cancer.